Search
Levocarnitine
go.drugbank.com/drugs/DB00583ApprovedInvestigationalConstituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.
Mixtures: BEAUTIFUL CONTRACT - Slimming contract -Hui Ju Sheng Enterprise Corporation Ltd.Products: LIPOVITASI-DApremilast
go.drugbank.com/drugs/DB05676ApprovedInvestigational[L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and
Perfluorohexyloctane
go.drugbank.com/drugs/DB17823ApprovedInvestigational[L46491] It is an inert, slightly amphiphilic compound. … [A259741] It was approved by the FDA on May 18, 2023 for the treatment of dry eye disease.[L46536]
Polyethylene glycol 300
go.drugbank.com/drugs/DB11161ApprovedPolyethylene glycol 300 (PEG 300) is a water-miscible polyether with an average molecular weight of 300 g/mol.
Benzoin resin
go.drugbank.com/drugs/DB11222ApprovedBenzoin resin is a balsamic resin obtained from the bark of several species of trees in the genus Styrax. There are two common kinds of benzoin, benzoin Siam and benzoin Sumatra, that are obtained from different species of the Styrax tre...
Mixtures: Blistex Kank-AOseltamivir
go.drugbank.com/drugs/DB00198ApprovedInvestigationalNotably, in 2017, the World Health Organization downgraded oseltamivir from its essential medicines list from a "core" drug to a "complementary" drug, due to limited cost-effectiveness. … [A179962, A179965, A179968] Due to the risk of adverse effects such as nausea, vomiting, psychiatric effects and renal adverse events in adults and vomiting in children, the harms are generally considered
Mavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigational[L50642] It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized
Ezogabine
go.drugbank.com/drugs/DB04953ApprovedWithdrawnFDA approved in June 10, 2011 under the name of ezogabine. … It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures
Umeclidinium
go.drugbank.com/drugs/DB09076ApprovedInvestigational[A7718,A7714] Umeclidinium was approved by the FDA in April 2014 under the brand name Incruse Ellipta as a standalone product.
Carbenicillin
go.drugbank.com/drugs/DB00578ApprovedBroad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.